Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: Lapatinib|DRUG: Capecitabine|DRUG: Octreotide
Sponsor: Novartis Pharmaceuticals